New manufacturing facility in Russia for Novo Nordisk
Novo Nordisk has opened a new formulation and filling facility for the production of insulin
Novo Nordisk has opened a new formulation and filling facility for insulin to treat diabetes. The new facility, located in Technopark Grabtsevo in the Kaluga region of Russia, will operate according to current Good Manufacturing Practice (cGMP). Production will cover both Penfill cartridges and the company’s FlexPen prefilled insulin injection pens for the Russian market.
‘The facility in Kaluga is a sign of our long-term commitment to people with diabetes in Russia, where, according to local studies, almost 10 million people have the disease. With our investment in local manufacturing, we’re ensuring the availability of high-quality insulin to Russian diabetics who rely on our products every day,’ said Lars Rebien Sørensen, CEO of Novo Nordisk.
This is the first and only Greenfield facility for the production of insulin in Russia. Environmental targets for CO2 emission, water consumption and energy use have been established, and with the construction of the new facility, Novo Nordisk has created approximately 150 new jobs.
‘Opening the facility in Kaluga is a sign of confidence in our region, as well as an important stage in the formation of a pharmaceutical cluster in Kaluga. I am convinced that the new facility will have a significant impact on improving the quality of life for people with diabetes in Kaluga as well as in the rest of Russia,’ said Kaluga Region Governor Anatoly Artamonov.
